The recent success in using low-dose combinations of kinase inhibitors to successfully treat pancreatic, NSCLC, breast, and colon cancer cell lines, PDX, and mouse tumor models (see (82) for a recent review) suggests that similar strategies may work with low-dose chromatin remodeling or SHP2 inhibitors in combination with low-dose kinase inhibitors (61, 83, 84). Here, PTPN11 is linked to malignant colon neoplasm.